RxDoctor Payments Data

Robert Sperry, MD

Family Medicine · Bellingham, WANPI 1417045550

Payments from drug & device makers

$2,177in general payments, 2019–2025

Across 154 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$376
  • Johnson & Johnson$277
  • Pfizer$222
  • Teva Pharmaceuticals USA, Inc.$201
  • Amgen$193
  • Novo Nordisk$178
  • plus $730 from 17 others

What the payments were for

  • Food & beverage$2,15799%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,177 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$80,330
Medicare patients
344
Services billed
3,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$62,747
EliquisApixaban29$34,234
OzempicSemaglutide15$19,722
XareltoRivaroxaban23$19,478
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$17,484
Tresiba Flextouch U-200Insulin Degludec14$8,158
Atorvastatin Calcium184$3,798
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,524
Omeprazole128$3,484
Rosuvastatin Calcium120$3,226
Tamsulosin Hcl87$2,534
Losartan Potassium128$2,175
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$1,961
Albuterol Sulfate HfaAlbuterol Sulfate82$1,895
Gabapentin85$1,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$95$62,74753 claims
PfizerEliquis, Paxlovid$222$35,62540 claims
Novo NordiskOzempic$178$19,72215 claims
Johnson & JohnsonXarelto$277$19,47823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →